Samuel L. Katz, MD, passed away on Monday, October 31, 2022. Dr. Katz was a world-renowned virologist, pediatrician, and chair emeritus and Wilburt C. Davison Professor Emeritus of Pediatrics at Duke University School of Medicine.

Monday, October 31, the Duke University Medical Center Archives hosts a casual open-house event of

In laboratory and primate tests, a new pan-coronavirus vaccine developed by the Duke Human Vaccine Institute (DHVI) has demonstrated wide protection against SARS-CoV-2 viruses and variants, including Omicron BA.5

A. Eugene Washington, M.D., chancellor for health affairs at Duke University and president and chief executive officer for the Duke University Health System, has announced that he will step down from the roles on June 30, 2023.

Many people incorrectly assume that having a disability lowers a person’s quality of life. Christopher Lunsford, MD, assistant professor of orthopaedic surgery, wants to change that misconception. Lunsford works to increase the conversation around disability as a facet of diversity, emphasizing that disability advocacy can and should be a focus of institutional excellence. Building a stronger disability consciousness, he says, can help improve treatment for patients and teaching for students and trainees.

Duke University’s Office for Translation & Commercialization continues to grow and set new records for commercializing innovations, according to just-released fiscal year 2022 data. Duke spawned 14 new companies in the fiscal year including four from the School of Medicine

When it comes to diseases like dementia, Parkinson’s, and ALS, Duke University cell biologist Chantell Evans thinks it’s time to look specifically at neurons. By unraveling how neurons deal with malfunctioning mitochondria, her work could open up possibilities for treating many currently incurable conditions.

It’s all too common for cancer patients to hear their doctors tell them they are no longer responding to their current treatment.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine 50 mg twice daily for 10 days for the treatment of mild-to-moderate COVID-19 symptoms.

Nicole Calakos, MD, PhD, a professor of neurology and Lincoln Financial Group Distinguished Professor of Neurobiology, has been elected to the U.S. National Academy of Medicine (NAM).